FDA approves first new CIDP treatment in decades

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Approves Argenx Drug as First New Treatment in Decades for Rare Nerve Disease CIDP Argenx's Vyvgart Hytrulo is now approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease that affects nerves and impairs muscle function. The drug, an FcRn inhibitor, is the first in its class to win FDA approval in CIDP. Sponsored The Value of Differential Diagnosis: A Catalight White Paper Presented by Catalight Learn how Catalight is working towards expanding care while simultaneously improving quality, accessibility, and affordability for families who need I/DD and ASD care. Download the white paper here!   Calling Digital Health Startups Does your organization specialize in Pediatric or Teen Behavioral Health? Then apply today to pitch your innovations and solutions at INVEST Digital Health taking place on September 18th in Dallas. Hurry the deadline is fast approaching. Submit Your Application Today

Featured News

Empowering Independence: The Rising Role of MLTSS in Medicaid Evolution Managed long-term services and supports (MLTSS) are emerging as essential lifelines for transformation. FTC Involvement Forces Novant Health to Scrap Its $320M Deal with CHS Novant Health called off its planned $320 million acquisition of two CHS-owned hospitals in North Carolina. The decision came after an appellate court granted the FTC an emergency injunction to block the deal — the agency had been challenging the deal for more than a year. Who Is Responsible for the High Cost of Prescription Drugs? One Advocate Weighs In Multiple stakeholders are to blame for prescription drug costs, including pharmaceutical companies and PBMs, according to Merith Basey, executive director of Patients for Affordable Drugs. Connected Healthcare: Solving the Challenges with Medical Devices Healthcare organizations must ensure that every solution incorporated into the connected ecosystem is designed and tested to validate that it is secure, compliant, and performs as expected. Unraveling Healthcare Innovation Spend: Where Healthtech Founders Need to Focus There is an urgent need for health systems to develop efficient strategies that balance improved patient outcomes with financial health — here are three areas to focus on.

Resources

MedCity FemFwd: What Needs To Happen to Improve Preeclampsia Rates? In this episode, we're joined by John Auerbach, senior vice president of federal health at consulting firm ICF. He discusses rising preeclampsia rates and how stakeholders need to act. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe